

LITERATURA

1. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. *Cancer Lett.* 2005 Sep 28;227(2):115-24. doi: 10.1016/j.canlet.2004.10.007. Epub 2004 Nov 19. PMID: 16112414.
2. Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. *Endocrinology.* 2003 Aug;144(8):3382-98. doi: 10.1210/en.2003-0192. PMID: 12865317.
3. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. *Clin Pharmacokinet.* 2007;46(2):133-57. doi: 10.2165/00003088-200746020-00003. PMID: 17253885.
4. Rodrigues AD. Drug Interactions Involving 17alpha-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition. *Clin Pharmacol Ther.* 2022 Jun;111(6):1212-1221. doi: 10.1002/cpt.2383. Epub 2021 Aug 24. PMID: 34342002.
5. Rose DP, Goldman M, Connolly JM, Strong LE. High-fiber diet reduces serum estrogen concentrations in premenopausal women. *Am J Clin Nutr.* 1991 Sep;54(3):520-5. doi: 10.1093/ajcn/54.3.520. PMID: 1652197.
6. Harrington WR, Sengupta S, Katzenellenbogen BS. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. *Endocrinology.* 2006 Aug;147(8):3843-50. doi: 10.1210/en.2006-0358. Epub 2006 May 11. PMID: 16690804.
7. Rodrigues AD. Drug Interactions Involving 17alpha-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition. *Clin Pharmacol Ther.* 2022 Jun;111(6):1212-1221. doi: 10.1002/cpt.2383. Epub 2021 Aug 24. PMID: 34342002.
8. Raps M, Helmerhorst F, Fleischer K, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. *J. Thromb. Haemost.* 2012;10:992-997. doi: 10.1111/j.1538-7836.2012.04720.x.
9. Odland V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? *Acta Obstet. Gynecol. Scand.* 2002;81:482-490. doi: 10.1034/j.1600-0412.2002.810603.x.
10. Mawet M, Maillard C, Klipping C, et al. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. *Eur. J. Contracept. Reprod. Health Care.* 2015;20:463-475. doi: 10.3109/13625187.2015.1068934.
11. Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. *Contraception.* 2021;103:213-221. doi: 10.1016/j.contraception.2021.01.001.
12. Kluff C, Zimmerman Y, Mawet M, et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. *Contraception.* 2017;95:140-147. doi: 10.1016/j.contraception.2016.08.018.
13. Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. *Contraception.* 2020;102:396-402. doi: 10.1016/j.contraception.2020.08.015.
14. Arnal JF, Scarabin PY, Trémollières F, et al. Estrogens in vascular biology and disease: Where do we stand today? *Curr. Opin. Lipidol.* 2007;18:554-560. doi: 10.1097/MOL.0b013e3282ef3bca.
15. Hodgins JB, Kregel JH, Reddick RL, et al. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. *J. Clin. Investig.* 2001;107:333-340. doi: 10.1172/JCI11320.
16. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, et al. Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: Results from a multiple-rising-dose study. *Menopause.* 2017;24:677-685. doi: 10.1097/GME.0000000000000823.

38.
AGU

38. Aktuální gastroenterologie
10. dubna 2025
09:00–16:30 hod.

**Ústřední vojenská nemocnice –
Vojenská fakultní nemocnice Praha
Kongresové centrum, pavilon CH2**

www.aktualnigastroenterologie.cz